Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ris-Rez

Phase 3

Ris-Rez is one of 16 therapeutic programs targeting Sarcoma. It is currently in Phase 3.

2

Indications

2

Total Trials

2

Active Trials

15

Competitors

Pipeline

Status by Indication[2][1]

Indication

SarcomaRecruiting

Neoplasms, LungRecruiting

SarcomaPreclinical

Recruiting

Neoplasms, LungPhase 3

Recruiting

Competition

Competitive Landscape

18 competitors in Sarcoma

#DrugCompanyPhaseTrials

Keytruda

Opdivo

Bristol-Myers Squibb

Tecentriq

IC-Green

PProvepharm SAS

Amtagvi

IIovance Biotherapeutics, Inc.

Talimogene Laherparepvec

Ris-Rez

NKTR-214

Bristol-Myers Squibb

Rapamune

PPrism Pharmaceuticals

Biological

NNational Environment Agency, Singapore

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 3Recruiting

Neoplasms, Lung

NCT07099898

Q4 2029

PreclinicalRecruiting

Sarcoma

NCT07602777

Clinical

Trials by Indication[1]

Neoplasms, Lung1 trial

Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)

Recruiting· GSK logo

GSK·Phase 3·NCT07099898·420 enrolled

Sarcoma1 trial

Phase 1b/2 Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Previously Treated Unresectable Advanced or Metastatic Sarcomas

Recruiting· GSK logo

GSK·Preclinical·NCT07602777·113 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ris-Rez. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ris-Rez. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: GSK

Related News